Lidocaine

INJECTABLE IMPLANT

PATIENT INFORMATION LEAFLET

1. General information

1.1 Name or Trade Name

RADIESSE® (+) Lidocaine Injectable implant

1.2 Device description

RADIESSE® (+) Lidocaine injectable implant contains synthetic calcium hydroxylapatite (a mineral) suspended in a gel that is mainly made up of water (sterile water for injection USP) together with glycerin (USP), sodium carboxymethylcellulose (USP), and 0.3% lidocaine hydrochloride. The lidocaine hydrochloride is a short-acting local anesthetic that will reduce discomfort when the product is injected into the skin. After injection, the gel gradually spreads away from the injection site, while the calcium hydroxylapatite remains in place adding volume and smoothing the skin. This effect typically lasts for about 6 months, but RADIESSE® (+) Lidocaine injectable implant has been shown to be effective for up to one year in some subjects. Additional injections (touch-ups) may be performed, but only after sufficient time has passed to allow your healthcare practitioner to make an evaluation.

RADIESSE® (+) Lidocaine injectable implant is indicated for plastic / reconstructive procedures. These include adding volume to the soft tissue of the facial area, restoring and correcting fat or volume loss (lipoatrophy) in the facial area, and rejuvenating the hands.

Studies have shown that a clinical effect of at least 6 months can be claimed for the following indications: human immunodeficiency virus (HIV)-related facial lipoatrophy, nasolabial folds, cheek augmentation, marionette lines, jawline and hand augmentation.

1.3 List of ingredients

Weight	Component
30 %	25-45µm calcium hydroxylapatite (CaHA) particles (v/v)
70 %	Gel (v/v), *consisting of the following in a buffer solution:* ○ 2.6 - 3.25 % sodium carboxymethylcellulose (w/v of buffer) ○ 15 % glycerin (w/w of buffer) ○ 50 mM sodium phosphate ○ 0.3 % lidocaine HCl (w/v)

Composition of the sodium buffer solution: sodium chloride (0.23 % w/w), sodium phosphate dibasic dihydrate (0.59 % w/w) sodium phosphate monobasic dihydrate (0.25 % w/w) and sterile water for injection (98.93 % w/w).

RADIESSE® (+) Lidocaine contains lidocaine hydrochloride, the most commonly used local anesthetic in dermatologic surgery. After injection, lidocaine hydrochloride is metabolized to 2,6-dimethylaniline (2,6-DMA).

Validated quality controls ensure that the DMA remaining in RADIESSE® (+) Lidocaine is within safe levels. If you have any concern or questions with regard to the residual DMA (e.g. if you know you are allergic), please consult your healthcare practitioner.

2. Contraindications (when the product must not be used)

- RADIESSE® (+) Lidocaine injectable implant is contraindicated in the presence of acute and/or chronic inflammation or infection involving the area to be treated.
- RADIESSE® (+) Lidocaine injectable implant is contraindicated if you have known hypersensitivity (allergy) to any of the components.
- RADIESSE® (+) Lidocaine injectable implant is not suitable if you have known hypersensitivity to lidocaine or anesthetics of the amide type.
- RADIESSE® (+) Lidocaine injectable implant is contraindicated if you are prone to developing inflammatory skin conditions or large and/or raised scars.
- The product must not be implanted into the upper layers of the skin or used as a skin replacement as doing so could cause complications such as fistula (hole through the skin), infections, extrusion (the product emerges through the skin onto the surface), nodules and hardening of the skin.
- RADIESSE® (+) Lidocaine injectable implant is not intended to be used for the correction of glabellar folds (frown lines) since there is a risk of necrosis (tissue death) and blocked arteries in the retina of the eye.
- RADIESSE® (+) Lidocaine injectable implant is contraindicated in the presence of foreign bodies such as liquid silicone or other particulate materials.
- RADIESSE® (+) Lidocaine injectable implant should not be used in areas where there is inadequate coverage of healthy tissue that is well supplied with blood vessels.
- RADIESSE® (+) Lidocaine injectable implant should not be used if you have a condition that causes poor wound healing or could affect the tissue over the implant.
- RADIESSE® (+) Lidocaine injectable implant is contraindicated if you have a bleeding disorder.

3. Warnings

- Special care is required when performing the injection, because complications may occur if the product is accidentally injected into a blood vessel. These include blocked blood vessels (embolism, occlusion) and impaired blood supply to the tissue (ischemia, infarction). When this occurs in the face, it may cause vision impairment, even blindness, stroke, skin necrosis (tissue death) and damage to facial structures. If you experience changes in vision, signs of a stroke, pale skin or unusual pain during or shortly after the procedure, your healthcare practitioner will immediately stop the injection and ensure you receive prompt medical attention.
- The implant should not be injected into an organ or structure which could be damaged by it.
- The implant should not be used if you are taking aspirin or other medication that could inhibit the healing process.
- The implant should not be placed in an open cavity as infection or extrusion may occur.
- Infection may damage or destroy the skin over the implant. Surgical drainage may be needed in the event of blood or serum accumulation at the injection site.

- If you experience a hypersensitivity/allergic reaction, this may lead to serious inflammation or infection so that it will be necessary to remove the implant.
- Injectable implants can cause various side effects, which are listed in section 5 below.
- It has not been established whether the product is effective and safe to use during pregnancy and breast-feeding or in people under the age of 18.
- It has not been established whether RADIESSE® (+) Lidocaine injectable implant can be used safely in the lips.

4. Precautions

- Your healthcare practitioner must familiarize themselves with the product and the associated product literature in order to minimize the risk of complications.
- The calcium hydroxylapatite (CaHA) particles in RADIESSE® (+) Lidocaine injectable implant are visible on CT scans and may be visible on X-rays. No errors of interpretation of CT scans occurred in a study of 58 patients with the RADIESSE® injectable implant (without lidocaine). Nevertheless, you must tell your primary care practitioners and/or radiologists that you have received this implant.
- The healthcare practitioner should observe standard precautions associated with injectable materials in order to minimize the risk of infection.
- RADIESSE® (+) Lidocaine injectable implant needs to be injected into soft tissue. It may not be as easily accepted if injected into scar tissue or damaged tissue.
- If infection occurring at the injection site proves untreatable, it may become necessary to remove the implant.
- Injection-related reactions, including bruising, erythema, swelling, pain, itching, discoloration or tenderness, may occur at the site of the injection. These usually disappear spontaneously within one to two days after the injection.
- Nodule(s) may form requiring treatment or removal.
- Irregularity of the implant may occur which may require a surgical procedure to correct.
- Tissue rupture may occur if too great a quantity is injected. This may require a surgical procedure to correct.
- RADIESSE® (+) Lidocaine injectable implant can be easily added in subsequent injections, but cannot be easily removed.
- There have been no clinical trials to show whether RADIESSE® (+) Lidocaine injectable implant is safe to use with other skin treatments, such as epilation, UV irradiation, radiofrequency, ablative or non-ablative laser, mechanical or chemical peeling procedures.
- The use of laser treatment, chemical peeling, or any other procedure based on an active response of the skin, after treatment with RADIESSE® (+) Lidocaine injectable implant creates a possible risk of inflammation at the implant site. This also applies if RADIESSE® (+) Lidocaine injectable implant is used before the skin has healed completely after such a procedure.
- If you have a history of cold sores caused by herpes virus, the virus may become reactivated by an injection of RADIESSE® (+) Lidocaine injectable implant.
- The safety of RADIESSE® injectable implant (without lidocaine) over a period of more than 3 years has not been investigated in clinical trials.
- You will need a careful risk-benefit assessment if you have congenital methemoglobinemia with glucose-6-phosphate dehydrogenase deficiency or if you are being treated with substances that induce methemoglobin.

5. Undesirable side effects

Side effects seen in a clinical trial with RADIESSE® (+) Lidocaine injectable implant were generally expected, mild in nature, and short in duration, the most common ones being swelling and redness. In the trial, RADIESSE® (+) Lidocaine injectable implant was used to treat nasolabial folds (laugh lines) on one side of the face and RADIESSE® injectable implant (without lidocaine) was used on the other side. The frequency of side effects was similar on both sides. The needle became jammed during 3/101 RADIESSE® (+) Lidocaine injectable implant injections, but no further problems occurred when the needle was replaced and the injection completed. Vascular compromise (full or partial interruption of blood supply to the tissue) occurred in 2/102 treatments with RADIESSE® injectable implant (without lidocaine) and none with RADIESSE® (+) Lidocaine injectable implant. Both occurrences of vascular compromise were treated successfully.

The following side effects were reported in clinical trials with RADIESSE® injectable implant (without lidocaine): bruising, swelling or puffiness, redness, nodules, lumps and bumps, pain, itching, soreness, tenderness, numbness, irritation, rash, needle jams, discoloration, hardness or firmness, headache, scab, tightness or stretching, bloodshot eyes, black eye, grazed skin, spots and pimples, sensitive nerves, sensation of dryness and burning, warmth, flushing, feeling feverish, ear discharge, hearing loss, blocked salivary gland.

- The following side effects have been reported since RADIESSE® injectable implant (without lidocaine) was placed on the market. These are voluntary reports made by an unknown number of people so it is not possible to estimate the frequency of the side effects or to establish whether all of them were actually caused by RADIESSE® injectable implant (without lidocaine): infection, including impetigo and cellulitis (infection of the deeper layers of the skin) and infection with herpes simplex and herpes zoster, loss of effect, product displacement/migration, allergic reactions including anaphylaxis, hives, rash, itching, swelling, inflammation including granuloma, pustules and abscesses and inflammation of the tissue surrounding the heart, necrosis (tissue death), nodules, hardness, redness, skin discoloration, pale skin, hair loss, pins and needles, drooping eyelids, pain, headache, asymmetry, bruising, blisters, dizziness, bags under the eyes, flu-like symptoms, Guillain-Barré syndrome (autoimmune disease affecting the nerves), rapid breathing, insufficient blood supply to tissues including in the eyes, enlarged lymph nodes, nausea, scarring, sensitivity to cold, blocked blood vessels, double vision, impairment/loss of vision, paralysis or weakness of facial muscles.

6. Residual risks (cannot be eliminated by risk minimization measures)

The overall residual risks, associated with the design and manufacture of the product, and the benefit/risk ratio of the devices when used according to the manufacturer's instructions for use are fully acceptable.

Please refer to the above safety information for details on residual risks of the product. Please ensure you follow the post-procedural care advice below and the directions from your healthcare professional to minimize procedural risk.

7. Reporting information

Adverse events are unintended and sometimes harmful occurrences, associated with the use of a therapeutic good, and include incidents involving medical devices. These can be reported to Merz Australia on our website at https://merzaustralia.com.au/adverse-event-reporting/ or to the TGA at https://www.tga.gov.au.

Contact your healthcare professional if you are experiencing any side effects or are concerned about any aspect of your treatment.

8. Additional information

Your suitability for the treatment will be assessed by your healthcare professional. The results of the treatment vary between patients and additional injections may sometimes be required. In clinical trials, RADIESSE® injectable implant (without lidocaine) was used for touch-up injections at 2 weeks and 4 weeks after the first treatment and repeat treatment after 6 to 12 months was shown also shown to be safe and effective. Your healthcare professional will design the right personal treatment plan for you and will decide if and when additional injections and repeat treatment should be given.

What to do after the treatment

Your healthcare professional will advise you on what you need to do after the procedure in order to promote normal healing and avoid complications. General guidelines include the following:

- Apply cool compresses to the injected areas for approximately 24 hours.
- If nodules appear, massage the area gently.
- Rest your face for a week by talking, smiling and laughing as little as possible.
- Do not worry about swelling and numbness since these are common occurrences. Swelling will usually disappear within 7 to 10 days, although it may persist for some weeks in some cases. Numbness should disappear within 4 to 6 weeks.

9. Implant card information

After the injection, you will be given an implant card, which contains information about your injection and the product that was used.

Keep this implant card with you and show it to your physician if you attend any other appointments. Information about previous treatment must be presented to your physician before repeat treatment.

Symbol	Title of symbol
	Patient name or ID
	Date of implantation
	Name and address of healthcare provider
	Number of injections
	Total volume injected
	Injections site(s)
	Catalogue number
	Information website for patients
	Name and address of the manufacturer
	Lot number
	Use-by-date

Legal Manufacturer

Manufacturer

Merz North America, Inc

4133 Courtney St., Suite 10

Franksville, WI 53126

USA

Australian Sponsor

Australian Sponsor Name and Address:

Merz Australia Pty Ltd

Level 3, 244 Coward Street

Mascot, NSW, 2020

Australia

Date of Issue and Version

Version: 01

2021-11-03